Table 2. Incidence and risk of de novo cancer development after kidney transplantation according to mTOR inhibitor treatment in time-dependent model.
| Outcome | With mTORi | Without mTORi | Adjusted HR* (95% CI) | p-value | ||
|---|---|---|---|---|---|---|
| Events | IR | Events | IR | |||
| Any cancer | 87 | 17.0 | 628 | 23.6 | 0.80 (0.60–1.09) | 0.16 |
| Kidney | 17 | 3.1 | 109 | 3.8 | 1.29 (0.62–2.66) | 0.50 |
| Bladder | 17 | 3.2 | 152 | 5.3 | 0.53 (0.28–1.00) | 0.05 |
| Lung | 3 | 0.6 | 26 | 0.9 | 0.65 (0.14–3.11) | 0.59 |
| Liver | 6 | 1.1 | 65 | 2.2 | 0.84 (0.28–2.56) | 0.76 |
| Colorectal | 4 | 0.7 | 27 | 0.9 | 1.73 (0.39–7.66) | 0.47 |
| Breast | 1 | 0.2 | 23 | 0.8 | 0.29 (0.03–3.27) | 0.32 |
| Hematological | 5 | 0.9 | 24 | 0.8 | 2.03 (0.46–8.92) | 0.35 |
| Skin | 1 | 0.2 | 4 | 0.1 | 5.66 (0.14–226) | 0.36 |
| Prostate | 3 | 0.6 | 17 | 0.6 | 1.26 (0.21–7.49) | 0.80 |
| Others | 30 | 5.6 | 208 | 7.3 | 0.73 (0.44–1.21) | 0.23 |
| Many cancers(≧2) | 3 | 0.6 | 35 | 1.3 | 1.12 (0.22–5.75) | 0.89 |
Notes:
IR: incidence rate, per 1,000 person-years.
*
Adjusted for age, gender, dialysis vintage, transplant within/overseas, DM, HTN, CHF, ACEi/ARB, Beta-blocker, Aspirin, NSAID, Statins, Cyclosporin, Tacrolimus, Mycophenolic acid, ATG.